The published article titled“Silencing of lncRNA CCDC26 Restrains the Growth and Migration of Glioma Cells In Vitro and In Vivo via Targeting miR-203”has been retracted fromOncology Research,Vol.26,No.8,2018,pp.1143...The published article titled“Silencing of lncRNA CCDC26 Restrains the Growth and Migration of Glioma Cells In Vitro and In Vivo via Targeting miR-203”has been retracted fromOncology Research,Vol.26,No.8,2018,pp.1143–1154.展开更多
Recent research has demonstrated the impact of physical activity on the prognosis of glioma patients,with evidence suggesting exercise may reduce mortality risks and aid neural regeneration.The role of the small ubiqu...Recent research has demonstrated the impact of physical activity on the prognosis of glioma patients,with evidence suggesting exercise may reduce mortality risks and aid neural regeneration.The role of the small ubiquitin-like modifier(SUMO)protein,especially post-exercise,in cancer progression,is gaining attention,as are the potential anti-cancer effects of SUMOylation.We used machine learning to create the exercise and SUMO-related gene signature(ESLRS).This signature shows how physical activity might help improve the outlook for low-grade glioma and other cancers.We demonstrated the prognostic and immunotherapeutic significance of ESLRS markers,specifically highlighting how murine double minute 2(MDM2),a component of the ESLRS,can be targeted by nutlin-3.This underscores the intricate relationship between natural compounds such as nutlin-3 and immune regulation.Using comprehensive CRISPR screening,we validated the effects of specific ESLRS genes on low-grade glioma progression.We also revealed insights into the effectiveness of Nutlin-3a as a potent MDM2 inhibitor through molecular docking and dynamic simulation.Nutlin-3a inhibited glioma cell proliferation and activated the p53 pathway.Its efficacy decreased with MDM2 overexpression,and this was reversed by Nutlin-3a or exercise.Experiments using a low-grade glioma mouse model highlighted the effect of physical activity on oxidative stress and molecular pathway regulation.Notably,both physical exercise and Nutlin-3a administration improved physical function in mice bearing tumors derived from MDM2-overexpressing cells.These results suggest the potential for Nutlin-3a,an MDM2 inhibitor,with physical exercise as a therapeutic approach for glioma management.Our research also supports the use of natural products for therapy and sheds light on the interaction of exercise,natural products,and immune regulation in cancer treatment.展开更多
Glioma is a severe malignant brain tumor marked by an exceedingly dire prognosis and elevated incidence of recurrence.The resilience of such tumors to chemotherapeutic agents,coupled with the formidable obstacle the b...Glioma is a severe malignant brain tumor marked by an exceedingly dire prognosis and elevated incidence of recurrence.The resilience of such tumors to chemotherapeutic agents,coupled with the formidable obstacle the blood-brain barrier(BBB)presents to most pharmacological interventions are major challenges in anti-glioma therapy.In an endeavor to surmount these impediments,we have synergized pH-sensitive nanoparticles carrying doxorubicin and apatinib to amplify the anti-neoplastic efficacy with cyclic arginine-glycine-aspartate acid(cRGD)modification.In this study,we found that the combination of doxorubicin(DOX)and apatinib(AP)showed a significant synergistic effect,achieved through cytotoxicity and induction of apoptosis,which might be due to the increased intracellular uptake of DOX following AP treatment.Besides,polycaprolactone-polyethylene glycol-cRGD(PCL-PEG-cRGD)drug carrier could cross the BBB by its targeting ability,and then deliver the drug to the glioma site via pH-responsive release,increasing the concentration of the drugs in the tumor.Meanwhile,DOX/AP-loaded PCL-PEGcRGD nanoparticles effectively inhibited cell proliferation,enhanced glioma cell apoptosis,and retarded tumor growth in vivo.These results collectively identified DOX/AP-loaded PCL-PEG-cRGD nanoparticles as a promising therapeutic candidate for the treatment of glioma.展开更多
To effectively penetrate the blood-brain barrier(BBB)and integrate magnetic resonance imaging(MRI)diagnosis and multitarget therapy for orthotopic glioma,we proposed to develop a multinuclear gadolinium(Gd)complex bas...To effectively penetrate the blood-brain barrier(BBB)and integrate magnetic resonance imaging(MRI)diagnosis and multitarget therapy for orthotopic glioma,we proposed to develop a multinuclear gadolinium(Gd)complex based on apoferritin(AFt).To this end,we rationally designed and synthesized a trinuclear Gd(Ⅲ)complex(Gd3)with strong T_(1)-weighted MRI performance and remarkable cytotoxicity against glioma cells in vitro.Subsequently,we constructed an AFt-Gd3 nanoparticle(NP)delivery system.AFt-Gd3 NPs not only penetrate BBB but also provide significant T_(1)-weighted MRI contrast for orthotopic glioma while effectively inhibiting glioma growth with minimal side effects in vivo.Furthermore,we elucidate the mechanism by which AFt-Gd3 NPs inhibit glioma growth:inducing apoptosis through chemodynamic therapy,blocking glutamine metabolism,and inhibiting energy metabolism.展开更多
The published article titled“Overexpression of miR-1283 Inhibits Cell Proliferation and Invasion of Glioma Cells by Targeting ATF4”has been retracted from Oncology Research,Vol.27,No.3,2019,pp.325–334.
Although with aggressive standards of care like surgical resection,chemotherapy,and radiation,high-grade gliomas(HGGs)and brain metastases(BM)treatment has remained challenging for more than two decades.However,techno...Although with aggressive standards of care like surgical resection,chemotherapy,and radiation,high-grade gliomas(HGGs)and brain metastases(BM)treatment has remained challenging for more than two decades.However,technological advances in this field and immunotherapeutic strategies have revolutionized the treatment of HGGs and BM.Immunotherapies like immune checkpoint inhibitors,CAR-T targeting,oncolytic virus-based therapy,bispecific antibody treatment,and vaccination approaches,etc.,are emerging as promising avenues offering new hope in refining patient’s survival benefits.However,selective trafficking across the blood-brain barrier(BBB),immunosuppressive tumor microenvironment(TME),metabolic alteration,and tumor heterogeneity limit the therapeutic efficacy of immunotherapy for HGGs and BM.Furthermore,to address this concern,the NanoBioTechnology-based bioinspired delivery system has been gaining tremendous attention in recent years.With technological advances such as Trojan horse targeting and infusing/camouflaging nanoparticles surface with biological molecules/cells like immunocytes,erythrocytes,platelets,glioma cell lysate and/or integrating these strategies to get hybrid membrane for homotypic recognition.These biomimetic nanotherapy offers advantages over conventional nanoparticles,focusing on greater target specificity,increased circulation stability,higher active loading capacity,BBB permeability(inherent inflammatory chemotaxis of neutrophils),decreased immunogenicity,efficient metabolism-based combinatorial effects,and prevention of tumor recurrence by induction of immunological memory,etc.provide new age of improved immunotherapies outcomes against HGGs and BM.In this review,we emphasize on neuro-immunotherapy and the versatility of these biomimetic nano-delivery strategies for precise targeting of hard-to-treat andmost lethal HGGs and BM.Moreover,the challenges impeding the clinical translatability of these approaches were addressed to unmet medical needs of brain cancers.展开更多
Glioma is the most common malignant tumor of the brain. The postoperative recurrence rate was high,and the 2-year survival rate only increased by 20%–25%. The reason is the blood-brain barrier(BBB). BBB is a physical...Glioma is the most common malignant tumor of the brain. The postoperative recurrence rate was high,and the 2-year survival rate only increased by 20%–25%. The reason is the blood-brain barrier(BBB). BBB is a physical barrier that stabilizes the physiological environment of brain tissue and protects the central nervous system from the invasion of harmful substances. Drug delivery based on nanotechnology and nanocarriers has attracted much attention due to its biological safety, continuous drug release time,increasing solubility, biological drug activity, and enhanced BBB permeability. By modifying different substances on the surface of nanocarriers, the BBB is bypassed by receptor-mediated and cell endocytosis and exocytosis. In addition, the purpose of bypassing BBB-targeted drug delivery can also be achieved by intranasal administration and local administration. This paper reviews different target transport mechanisms, mainly in invasive and non-invasive strategies, the nanocarriers that have made progress and the nanocarrier strategy of bypassing BBB are listed.展开更多
The published article titled“MicroRNA-181b Inhibits Cellular Proliferation and Invasion of Glioma Cells via Targeting Sal-Like Protein 4”has been retracted from Oncology Research,Vol.25,No.6,2017,pp.947–957.
Gliomas are the most common intracranial tumors with poor survival and high mortality.Furthermore,the clinical efficacy of current drugs is still not ideal;despite the development of several therapeutic drugs over the...Gliomas are the most common intracranial tumors with poor survival and high mortality.Furthermore,the clinical efficacy of current drugs is still not ideal;despite the development of several therapeutic drugs over the past decades and tumor progression or recurrence is inevitable in many patients.RNAibased therapy presents a novel disease-related gene targeting therapy,including otherwise undruggable genes,and generates therapeutic options.However,the therapeutic effect of siRNA is hindered by multiple biological barriers,primarily the blood-brain barrier(BBB).A glycoprotein-derived peptide-mediated delivery system is the preferred option to resolve this phenomenon.RDP,a polypeptide composed of 15 amino acids derived from rabies virus glycoprotein(RVG),possesses an N-type acetylcholine receptor(nAChR)-binding efficiency similar to that of RVG29.Given its lower cost and small particle size when used as a ligand,RDP should be extensively evaluated.First,we verified the brain-targeting efficacyy of RDP at the cellular and animal levels and further explored the possibility of using the RDP-oligoarginine peptide(designated RDP-5R)as a bio-safe vehicle to deliver therapeutic siRNA into glioma cells in vitro and in vivo.The polypeptide carrier possesses a diblock design composed of oligoarginine for binding siRNA through electrostatic interactions and RDP for cascade BBB-and glioma cell-targeting.The results indicated that RDP-R5/siRNA nanoparticles exhibited stable and suitable physicochemical properties for in vivo application,desirable glioma-targeting effects,and therapeutic efficiency.As a novel and efficient polypeptide carrier,RDP-based polypeptides hold great promise as a noninvasive,safe,and efficient treatment for various brain diseases.展开更多
There remain several intractable challenges for chemotherapy in glioma treatment,including the blood-brain barrier(BBB),blood-brain tumor barrier(BBTB),and tumor heterogeneity caused by cancer stem cells(CSCs),which a...There remain several intractable challenges for chemotherapy in glioma treatment,including the blood-brain barrier(BBB),blood-brain tumor barrier(BBTB),and tumor heterogeneity caused by cancer stem cells(CSCs),which are resistant to conventional chemotherapy.Here,we established a nano strategy to kill glioma cells and CSCs,combining carfilzomib and bis(diethyldithiocarbamate)copper.The synergistic drug combination disturbed cell protein metabolism at different stages and induced apoptosis and cuproptosis.The Y-shaped targeting ligand pHA-VAP-modified nanodiscs were designed to help the chemotherapeutic agents cross the BBB/BBTB and finally accumulate in tumor site.This all-stage targeting and all-stage treatment nanomedicine significantly prolonged the survival in glioma-bearing mice and might inspire the rational design of advanced drug delivery platforms.展开更多
Background and Objective Patients with glioma experience a high symptom burden and have diverse palliative care needs.However,the assessment scales used in palliative care remain non-standardized and highly heterogene...Background and Objective Patients with glioma experience a high symptom burden and have diverse palliative care needs.However,the assessment scales used in palliative care remain non-standardized and highly heterogeneous.To evaluate the application patterns of the current scales used in palliative care for glioma,we aim to identify gaps and assess the need for disease-specific scales in glioma palliative care.Methods We conducted a systematic search of five databases including PubMed,Web of Science,Medline,EMBASE,and CINAHL for quantitative studies that reported scale-based assessments in glioma palliative care.We extracted data on scale characteristics,domains,frequency,and psychometric properties.Quality assessments were performed using the Cochrane ROB 2.0 and ROBINS-I tools.Results Of the 3,405 records initially identified,72 studies were included.These studies contained 75 distinct scales that were used 193 times.Mood(21.7%),quality of life(24.4%),and supportive care needs(5.2%)assessments were the most frequently assessed items,exceeding half of all scale applications.Among the various assessment dimensions,the Distress Thermometer(DT)was the most frequently used tool for assessing mood,while the Short Form-36 Health Survey Questionnaire(SF-36)was the most frequently used tool for assessing quality of life.The Mini Mental Status Examination(MMSE)was the most common tool for cognitive assessment.Performance status(5.2%)and social support(6.8%)were underrepresented.Only three brain tumor-specific scales were identified.Caregiver-focused scales were limited and predominantly burden-oriented.Conclusions There are significant heterogeneity,domain imbalances,and validation gaps in the current use of assessment scales for patients with glioma receiving palliative care.The scale selected for use should be comprehensive and user-friendly.展开更多
Astragalus extract Astragalus polysaccharide(APS),a natural extract,has been demonstrated to exert inhibitory effects on the development of various tumors by modulating microRNA(miRNA).However,the precise regulatory m...Astragalus extract Astragalus polysaccharide(APS),a natural extract,has been demonstrated to exert inhibitory effects on the development of various tumors by modulating microRNA(miRNA).However,the precise regulatory mechanism of miRNA-223(miR-223)in brain glioma cells remains unclear.This study aimed to investigate the inhibitory effect of Astragalus extract APS on brain glioma cells through the miR-223/FBXW7 signaling pathway and its potential mechanism.Using the TargetScan tool,we predicted the binding between miR-223 and FBXW7 and confirmed this binding relationship through dual luciferase assay.We compared the expression of miR-223 and FBXW7 in glioma and adjacent tissues and followed up the prognosis.U87 cells were subjected to APS treatment or were transfected with small interfering RNA(siRNA)of miR-223 mimics to examine the effects of these treatments on cell proliferation,apoptosis,and FBXW7 expression.Our results demonstrated that miR-223 directly bound to FBXW7,as confirmed by dual luciferase assay.Moreover,the mRNA expression of miR-223 in glioma tissues was higher than that in paracancerous tissues,while the mRNA and protein levels of FBXW7 in glioma tissues were lower than those in paracancerous tissues.In addition,we observed a negative correlation between the expression of miR-223 and FBXW7(P<0.05).APS significantly inhibited the proliferation and invasion of U87 cells,suppressed the expression of miR-223,and promoted the expression of FBXW7(P<0.05).Transfection of miR-223 mimic into cells reversed the inhibition of miR-223 and the increase of FBXW7 induced by APS(P<0.05).Therefore,our findings suggested that APS might inhibit the proliferation and invasion of the glioma cell line U87 through the miR-223/FBXW7 signaling pathway.展开更多
Patients with glioma have a very high mortality rate,thus improving the poor prognosis of glioma has been the goal in the therapeutic field.Searching for more effective drugs for gliomas from natural compounds is a pr...Patients with glioma have a very high mortality rate,thus improving the poor prognosis of glioma has been the goal in the therapeutic field.Searching for more effective drugs for gliomas from natural compounds is a promising strategy.In this study,both oleanonic acid and oleanolic acid inhibited proliferation of glioma cells and reduced expression of cyclin D1 and E1,but the former has a lower IC_(50)than the latter.Oleanonic acid reduced the expression of p-STAT3 but not p-STAT1 and 5,and also reducing the expression of STAT3 in the nucleus and its transcriptional activity in glioma cells.Furthermore,knockdown of STAT3 expression inhibited proliferation and migration of glioma cells.Next,the expressions of the upstream regulators such as SIRT6 and p-JAK2 but not SIRT1,p-ERK1/2,p300 were increased by oleanonic acid.The overexpression of SIRT6 not only reduced the expression of p-STAT3 and its transcriptional activity but also inhibited the proliferation and migration of glioma cells.In addition,the effects that oleanonic acid reduced the expression of p-STAT3 and its transcriptional activity and inhibited the proliferation and migration were attenuated by the knockdown of SIRT6.Furthermore,oleanonic acid effectively suppressed glioma growth and extended survival in nude mice bearing intracerebral U87 xenografts,but not in nude mice bearing intracerebral SIRT6-knockdown U87xenografts.In conclusion,oleanonic acid upregulates the expression of SIRT6 to inactivates STAT3 and then inhibits glioma growth.展开更多
Accurate genotyping and prognosis of glioma patients present significant clinical challenges,often dependent on subjective judgement and insufficient scientific evidence.This study aims to develop a robust,noninvasive...Accurate genotyping and prognosis of glioma patients present significant clinical challenges,often dependent on subjective judgement and insufficient scientific evidence.This study aims to develop a robust,noninvasive preoperative multi-modal MRIbased transformer learning model to predict IDH genotyping and glioma prognosis.This multi-centre study included 563 glioma patients to develop an interpretable classification model utilising various preoperative imaging sequences,including T1-weighted,T2-weighted,fluid-attenuated inversion recovery,contrast-enhanced T1-weighted,and diffusion-weighted imaging.The model employs a multi-task learning framework to extract and fuse radiomic,deep learning,and clinical features for IDH genotyping and glioma prognosis.Additionally,a multi-modal transformer strategy is integrated to analyse structural and functional MRI,thereby enhancing model performance.Experimental results indicate that the model demonstrates superior performance,surpassing previous research and other state-of-the-art methods.The model achieves an AUC of 91.40% in the IDH genotyping task and 93.37% in the glioma prognosis task.Group analysis reveals that the model exhibits higher sensitivity to IDH-mutant cases and more accurately identifies low-risk groups compared to medium-or high-risk groups.This study aims to achieve accurate IDH genotyping and glioma prognosis through effective classification method,offering valuable diagnostic insights for clinical practice and expediting treatment decisions.展开更多
Background:PLK3,which played an important role in cell cycle progression and stress response,was identified as highly expressed in various carcinomas.However,the functions,molecular characteristics,and prognostic valu...Background:PLK3,which played an important role in cell cycle progression and stress response,was identified as highly expressed in various carcinomas.However,the functions,molecular characteristics,and prognostic value of PLK3 in glioma remained unexplored.Methods:We analyzed PLK3 expression in glioma samples from multiple databases.Both overexpression and knockdown of Plk3 were performed to investigate tumor cell growth in glioma,and the transplanted glioma mouse model demonstrated the role of Plk3 on tumor progression.Immunohistochemistry was conducted to detect PLK3 expression and immune cell infiltration.The trans-well assay for PLK3 on the immune cells recruitment was also determined.Additionally,we further evaluated the correlation between PLK3 and PD-1/PD-L1 as well as other immune checkpoints.Results:We found that an increased level of PLK3 was associated with malignancy and poor prognosis of glioma,and further validated that PLK3 promoted glioma progression.PLK3 also played a crucial role in immune response and was involved in Tcell immune suppression.Specifically,we revealed that CD8^(+)and CD4^(+)Tcell infiltration was decreased in Plk3 overexpressed xenografts.Furthermore,it was predicted that PLK3 was synergistic with other checkpoint members in glioma.In general,high expression of PLK3 was associated with a malignant process and poor prognosis in glioma patients.Conclusion:Our findings indicated that PLK3 expression level was highly correlated to the malignancy of gliomas,and we validated that PLK3 could promote the GBM progress in vitro and in vivo.Furthermore,PLK3 played important roles in Tcell and neutrophil immune response in glioma.Besides,the conspicuous association between PLK3 and other immune checkpoints was also observed.Crucially,high-level PLK3 expression was revealed to be related to poor clinical prognosis.These results demonstrated that PLK3 may serve as a prognostic biomarker and a potential target for glioma.展开更多
Objectives:Fear of recurrence(FoR)is a common psychological burden in cerebral glioma patients.Spousal emotional support and self-disclosure may help mitigate FoR,yet their roles in this population are unclear.This st...Objectives:Fear of recurrence(FoR)is a common psychological burden in cerebral glioma patients.Spousal emotional support and self-disclosure may help mitigate FoR,yet their roles in this population are unclear.This study aimed to explore the association between FoR,spousal emotional support,and self-disclosure in patients with cerebral glioma.Methods:Patients with cerebral glioma were assessed using the Fear of Progression Questionnaire-Short Form(FoP-Q-SF),Perceived Social Support Scale(PSSS),Distress Disclosure Index(DDI),and Acceptance and Action Questionnaire(AAQ).Pearson correlation analysis was conducted to examine the relationships among the scale scores,while multiple linear regression analysis was performed to identify factors influencing FoR in these patients.A structural equation model(SEM)was constructed to analyze the pathways of influence among FoR,spousal emotional support,and self-disclosure.Results:FoR was significantly negatively correlated with spousal emotional support,self-disclosure,and psychological flexibility(r=−0.3986,−0.3206,−0.4547,respectively;all p<0.05),while spousal emotional support and self-disclosure were significantly positively correlated with psychological flexibility(r=0.2457,0.2776,respectively;all p<0.05).Regression analysis revealed that self-funded medical insurance,unmarried/other marital status,lack of religious belief,and lower scores of spousal emotional support,self-disclosure,and psychological flexibility were risk factors for increased FoR.The SEM demonstrated an acceptable model fit.Psychological flexibility was found to mediate the relationship between self-disclosure and FoR,indicating that self-disclosure not only had a direct negative effect on FoR but also exerted an indirect negative effect through its positive influence on psychological flexibility.Conclusion:FoR is prevalent among patients with cerebral glioma.Spousal emotional support and self-disclosure were identified as independent influencing factors of FoR.While spousal emotional support directly affected FoR,self-disclosure influenced it both directly and indirectly through the mediation of psychological flexibility.展开更多
Objective Glioma is a highly heterogeneous and malignant intracranial tumor that presents challenges for clinical treatment.ELMO domain containing 2(ELMOD2)is a GTPase-activating protein that regulates a range of cell...Objective Glioma is a highly heterogeneous and malignant intracranial tumor that presents challenges for clinical treatment.ELMO domain containing 2(ELMOD2)is a GTPase-activating protein that regulates a range of cellular biological processes.However,its specific role and prognostic value in tumorigenesis are still unknown.This study aimed to assess the prognostic relevance and signaling function of ELMOD2 in gliomas.Methods The Chinese Glioma Genome Atlas(CGGA)and The Cancer Genome Atlas(TCGA)databases were utilized to conduct a comprehensive analysis of the expression profile of ELMOD2 in gliomas,elucidating its associations with clinicopathological parameters and patient prognosis.Single-cell analysis was performed to characterize ELMOD2 expression across distinct glioma cell subpopulations.Gene Ontology(GO),Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses,and Gene Set Variation Analysis(GSVA)were employed to evaluate the potential biological functions of ELMOD2 in gliomagenesis.Specific small interfering RNAs(siRNAs)were used to knock down ELMOD2 in the glioma cell lines U251 and A172 to assess their cellular behaviors and examine the levels of multiple key signaling molecules associated with the occurrence of gliomas.Results ELMOD2 was overexpressed in gliomas,and this upregulation was correlated with tumor grade,isocitrate dehydrogenase mutation,and 1p/19q codeletion status.Notably,ELMOD2 expression was elevated in classical and mesenchymal subtypes,and single-cell resolution analysis revealed predominant enrichment within malignant cells.Functionally,ELMOD2 regulated cell cycle progression,and its overexpression was related to independent adverse outcomes.In vitro experiments revealed that ELMOD2 was located in the cytoplasm and nucleoplasm.Furthermore,ELMOD2 knockdown reduced proliferation,migration,and invasion and increased apoptosis in U251 and A172 cell lines.Finally,ELMOD2 knockdown significantly decreased p-Erk1/2.Conclusions ELMOD2 expression in glioma is positively correlated with tumorigenesis and is a crucial independent prognostic marker.Thus,ELMOD2 is a promising biomarker and therapeutic target for glioma treatment.展开更多
Objective:To systematically explore the effectiveness of combining Enhanced Recovery After Surgery(ERAS)nursing and empathy intervention for postoperative patients with glioma.Methods:A total of 54 patients with gliom...Objective:To systematically explore the effectiveness of combining Enhanced Recovery After Surgery(ERAS)nursing and empathy intervention for postoperative patients with glioma.Methods:A total of 54 patients with glioma undergoing surgical treatment were selected for the study.The patients were admitted to the hospital between April 2023 and April 2025.The patients were divided into an observation group(n=27)and a control group(n=27)based on a random number table method.Relevant intervention indicators were compared between the two groups.Results:Compared with the control group,the postoperative recovery indicators in the observation group showed significant differences(P<0.05).After intervention,the scores of stress psychological indicators,FMA,NHISS,and ADL in the observation group were all better than those in the control group(P<0.05).The incidence of complications in the observation group was significantly lower than that in the control group(P<0.05).Conclusion:The combined application of empathy intervention and ERAS nursing effectively regulates the postoperative stress psychological state of patients with glioma,significantly improves their limb and neurological functions as well as daily living abilities,accelerates postoperative recovery,and reduces complications.This approach is feasible for wider implementation.展开更多
Objectives:Glioma,as the most lethal primary brain malignancy with poor prognosis,requires further elucidation on the functional role of long noncoding RNA(lncRNA)DDX11 antisense RNA 1(DDX11-AS1)in its pathogenesis,de...Objectives:Glioma,as the most lethal primary brain malignancy with poor prognosis,requires further elucidation on the functional role of long noncoding RNA(lncRNA)DDX11 antisense RNA 1(DDX11-AS1)in its pathogenesis,despite its established oncogenic functions in other cancers.Therefore,this study sought to characterize the oncogenic role and molecular mechanism of DDX11-AS1 in glioma.Methods:DDX11-AS1 expression levels were analyzed in clinical surgical glioma specimens and publicly available datasets.The functional roles of DDX11-AS1 on glioma cell proliferation and migration were investigated using in vitro knockdown and overexpression assays.In vivo tumor growth was assessed using orthotopic glioma-bearing mouse models.To elucidate the regulatory axis involving DDX11-AS1,miR-1183,and E2F transcription factor 7(E2F7),we performed competitive endogenous RNA(ceRNA)analysis and conducted functional rescue experiments via miR-1183 inhibition.Results:DDX11-AS1 expression was markedly upregulated in clinical glioma specimens.Functionally,DDX11-AS1 knockdown significantly suppressed glioma cell proliferation and migration in vitro,while its overexpression exacerbated these malignant phenotypes.Orthotopic glioma-bearingmouse models confirmed that DDX11-AS1 drives in vivo glioma tumor growth.Mechanistically,DDX11-AS1 functions as a ceRNA by competitively interacting with miR-1183.Critically,inhibition of miR-1183 rescued the suppressive effects of DDX11-AS1 knockdown on glioma tumorigenic phenotypes and restored E2F7 expression levels.Conclusions:This study demonstrates that lncRNA DDX11-AS1 promotes glioma progression by regulating the miR-1183/E2F7 axis,indicating a potential therapeutic target for glioma.展开更多
Background:Glioma is the most common tumor of the central nervous system with a poor prognosis.This study aims to explore the role of calcium/calmodulin-dependent protein kinase IIβ(CAMK2B)in regulating the malignant...Background:Glioma is the most common tumor of the central nervous system with a poor prognosis.This study aims to explore the role of calcium/calmodulin-dependent protein kinase IIβ(CAMK2B)in regulating the malignant progression of glioma cells,as well as the molecular mechanisms underlying these malignant behaviors.Methods:The correlation between CAMK2B expression in gliomas and patient prognosis was analyzed using immunohistochemistry,quantitative reverse transcription polymerase chain reaction(qRT-PCR),and western blot.Furthermore,the study explored the role of CAMK2B in glioma cell proliferation,invasion,and migration using cell counting kit-8(CCK-8),5-Ethynyl-2′-deoxyuridine(EdU),wound healing,transwell,and in vivo tumor xenograft assays.Result:Patients with high CAMK2B expression exhibited significantly better prognostic outcomes compared to those with low expression levels.Furthermore,CAMK2B expression was significantly lower in glioma tissues and cells compared to both normal brain tissue and human astrocyte cell lines.Notably,overexpression of CAMK2B in glioma cells led to an approximate 40%reduction in proliferative capacity and a 60–70%decrease in invasive and migratory abilities,compared to control glioma cells.These differences were statistically significant at p<0.05.Conversely,knockdown of CAMK2B using siRNA-CAMK2B significantly enhanced the proliferative,invasive,and migratory capabilities of glioma cells in both in vitro and in vivo settings,enhancing these abilities by 1.5 to 3 times.Notably,these effects were reversed through the application of the Rat Sarcoma viral oncogene homolog(Ras)pathway inhibitor,Salirasib.Western blot analysis revealed that knockdown of CAMK2B led to activation of the Ras/Rapidly Accelerated Fibrosarcoma(Raf)/Mitogen-activated protein kinase kinase(MEK)/Extracellular signal-regulated kinase(ERK)signaling pathway in glioma cell lines,whereas overexpression of CAMK2B resulted in the suppression of this pathway.Conclusion:CAMK2B inhibits glioma proliferation,invasion,andmigration through the Ras/Raf/MEK/ERK signaling pathway.展开更多
文摘The published article titled“Silencing of lncRNA CCDC26 Restrains the Growth and Migration of Glioma Cells In Vitro and In Vivo via Targeting miR-203”has been retracted fromOncology Research,Vol.26,No.8,2018,pp.1143–1154.
基金supported by Project of the Health Shanghai Initiative Special Fund(Medical-Sports Integration,Creating a New Model of Exercise for Health),No.JKSHZX-2022-02(to SC).
文摘Recent research has demonstrated the impact of physical activity on the prognosis of glioma patients,with evidence suggesting exercise may reduce mortality risks and aid neural regeneration.The role of the small ubiquitin-like modifier(SUMO)protein,especially post-exercise,in cancer progression,is gaining attention,as are the potential anti-cancer effects of SUMOylation.We used machine learning to create the exercise and SUMO-related gene signature(ESLRS).This signature shows how physical activity might help improve the outlook for low-grade glioma and other cancers.We demonstrated the prognostic and immunotherapeutic significance of ESLRS markers,specifically highlighting how murine double minute 2(MDM2),a component of the ESLRS,can be targeted by nutlin-3.This underscores the intricate relationship between natural compounds such as nutlin-3 and immune regulation.Using comprehensive CRISPR screening,we validated the effects of specific ESLRS genes on low-grade glioma progression.We also revealed insights into the effectiveness of Nutlin-3a as a potent MDM2 inhibitor through molecular docking and dynamic simulation.Nutlin-3a inhibited glioma cell proliferation and activated the p53 pathway.Its efficacy decreased with MDM2 overexpression,and this was reversed by Nutlin-3a or exercise.Experiments using a low-grade glioma mouse model highlighted the effect of physical activity on oxidative stress and molecular pathway regulation.Notably,both physical exercise and Nutlin-3a administration improved physical function in mice bearing tumors derived from MDM2-overexpressing cells.These results suggest the potential for Nutlin-3a,an MDM2 inhibitor,with physical exercise as a therapeutic approach for glioma management.Our research also supports the use of natural products for therapy and sheds light on the interaction of exercise,natural products,and immune regulation in cancer treatment.
基金supported by Sichuan Science and Technology Program,China(No.2023YFS0273)the 1·3·5 Project for Disciplines of Excellence,West China Hospital,Sichuan University,China(No.ZYJC21022).
文摘Glioma is a severe malignant brain tumor marked by an exceedingly dire prognosis and elevated incidence of recurrence.The resilience of such tumors to chemotherapeutic agents,coupled with the formidable obstacle the blood-brain barrier(BBB)presents to most pharmacological interventions are major challenges in anti-glioma therapy.In an endeavor to surmount these impediments,we have synergized pH-sensitive nanoparticles carrying doxorubicin and apatinib to amplify the anti-neoplastic efficacy with cyclic arginine-glycine-aspartate acid(cRGD)modification.In this study,we found that the combination of doxorubicin(DOX)and apatinib(AP)showed a significant synergistic effect,achieved through cytotoxicity and induction of apoptosis,which might be due to the increased intracellular uptake of DOX following AP treatment.Besides,polycaprolactone-polyethylene glycol-cRGD(PCL-PEG-cRGD)drug carrier could cross the BBB by its targeting ability,and then deliver the drug to the glioma site via pH-responsive release,increasing the concentration of the drugs in the tumor.Meanwhile,DOX/AP-loaded PCL-PEGcRGD nanoparticles effectively inhibited cell proliferation,enhanced glioma cell apoptosis,and retarded tumor growth in vivo.These results collectively identified DOX/AP-loaded PCL-PEG-cRGD nanoparticles as a promising therapeutic candidate for the treatment of glioma.
基金supported by the Natural Science Foundation of Guangxi(2022GXNSFGA035003)Natural Science Foundation of China(82404419,22077021)the Guangxi"Bagui"Scholar Program to F.Y.
文摘To effectively penetrate the blood-brain barrier(BBB)and integrate magnetic resonance imaging(MRI)diagnosis and multitarget therapy for orthotopic glioma,we proposed to develop a multinuclear gadolinium(Gd)complex based on apoferritin(AFt).To this end,we rationally designed and synthesized a trinuclear Gd(Ⅲ)complex(Gd3)with strong T_(1)-weighted MRI performance and remarkable cytotoxicity against glioma cells in vitro.Subsequently,we constructed an AFt-Gd3 nanoparticle(NP)delivery system.AFt-Gd3 NPs not only penetrate BBB but also provide significant T_(1)-weighted MRI contrast for orthotopic glioma while effectively inhibiting glioma growth with minimal side effects in vivo.Furthermore,we elucidate the mechanism by which AFt-Gd3 NPs inhibit glioma growth:inducing apoptosis through chemodynamic therapy,blocking glutamine metabolism,and inhibiting energy metabolism.
文摘The published article titled“Overexpression of miR-1283 Inhibits Cell Proliferation and Invasion of Glioma Cells by Targeting ATF4”has been retracted from Oncology Research,Vol.27,No.3,2019,pp.325–334.
文摘Although with aggressive standards of care like surgical resection,chemotherapy,and radiation,high-grade gliomas(HGGs)and brain metastases(BM)treatment has remained challenging for more than two decades.However,technological advances in this field and immunotherapeutic strategies have revolutionized the treatment of HGGs and BM.Immunotherapies like immune checkpoint inhibitors,CAR-T targeting,oncolytic virus-based therapy,bispecific antibody treatment,and vaccination approaches,etc.,are emerging as promising avenues offering new hope in refining patient’s survival benefits.However,selective trafficking across the blood-brain barrier(BBB),immunosuppressive tumor microenvironment(TME),metabolic alteration,and tumor heterogeneity limit the therapeutic efficacy of immunotherapy for HGGs and BM.Furthermore,to address this concern,the NanoBioTechnology-based bioinspired delivery system has been gaining tremendous attention in recent years.With technological advances such as Trojan horse targeting and infusing/camouflaging nanoparticles surface with biological molecules/cells like immunocytes,erythrocytes,platelets,glioma cell lysate and/or integrating these strategies to get hybrid membrane for homotypic recognition.These biomimetic nanotherapy offers advantages over conventional nanoparticles,focusing on greater target specificity,increased circulation stability,higher active loading capacity,BBB permeability(inherent inflammatory chemotaxis of neutrophils),decreased immunogenicity,efficient metabolism-based combinatorial effects,and prevention of tumor recurrence by induction of immunological memory,etc.provide new age of improved immunotherapies outcomes against HGGs and BM.In this review,we emphasize on neuro-immunotherapy and the versatility of these biomimetic nano-delivery strategies for precise targeting of hard-to-treat andmost lethal HGGs and BM.Moreover,the challenges impeding the clinical translatability of these approaches were addressed to unmet medical needs of brain cancers.
基金supported by the National Natural Science Foundation of China (Nos. 22074072, 22274083)the Shandong Provincial Natural Science Foundation (Nos. ZR2022LZY022, ZR2023LZY005)+2 种基金the Science and Technology Planning Project of South District of Qingdao City (No. 2022–4–005-YY)the Exploration project of the State Key Laboratory of Bio Fibers and Eco Textiles of Qingdao University (No. TSKT202101)the High-Level Discipline Project of Shandong Province。
文摘Glioma is the most common malignant tumor of the brain. The postoperative recurrence rate was high,and the 2-year survival rate only increased by 20%–25%. The reason is the blood-brain barrier(BBB). BBB is a physical barrier that stabilizes the physiological environment of brain tissue and protects the central nervous system from the invasion of harmful substances. Drug delivery based on nanotechnology and nanocarriers has attracted much attention due to its biological safety, continuous drug release time,increasing solubility, biological drug activity, and enhanced BBB permeability. By modifying different substances on the surface of nanocarriers, the BBB is bypassed by receptor-mediated and cell endocytosis and exocytosis. In addition, the purpose of bypassing BBB-targeted drug delivery can also be achieved by intranasal administration and local administration. This paper reviews different target transport mechanisms, mainly in invasive and non-invasive strategies, the nanocarriers that have made progress and the nanocarrier strategy of bypassing BBB are listed.
文摘The published article titled“MicroRNA-181b Inhibits Cellular Proliferation and Invasion of Glioma Cells via Targeting Sal-Like Protein 4”has been retracted from Oncology Research,Vol.25,No.6,2017,pp.947–957.
基金supported by CAMS Innovation Fund for Medical Sciences(No.2021-I2M-1-026,China).
文摘Gliomas are the most common intracranial tumors with poor survival and high mortality.Furthermore,the clinical efficacy of current drugs is still not ideal;despite the development of several therapeutic drugs over the past decades and tumor progression or recurrence is inevitable in many patients.RNAibased therapy presents a novel disease-related gene targeting therapy,including otherwise undruggable genes,and generates therapeutic options.However,the therapeutic effect of siRNA is hindered by multiple biological barriers,primarily the blood-brain barrier(BBB).A glycoprotein-derived peptide-mediated delivery system is the preferred option to resolve this phenomenon.RDP,a polypeptide composed of 15 amino acids derived from rabies virus glycoprotein(RVG),possesses an N-type acetylcholine receptor(nAChR)-binding efficiency similar to that of RVG29.Given its lower cost and small particle size when used as a ligand,RDP should be extensively evaluated.First,we verified the brain-targeting efficacyy of RDP at the cellular and animal levels and further explored the possibility of using the RDP-oligoarginine peptide(designated RDP-5R)as a bio-safe vehicle to deliver therapeutic siRNA into glioma cells in vitro and in vivo.The polypeptide carrier possesses a diblock design composed of oligoarginine for binding siRNA through electrostatic interactions and RDP for cascade BBB-and glioma cell-targeting.The results indicated that RDP-R5/siRNA nanoparticles exhibited stable and suitable physicochemical properties for in vivo application,desirable glioma-targeting effects,and therapeutic efficiency.As a novel and efficient polypeptide carrier,RDP-based polypeptides hold great promise as a noninvasive,safe,and efficient treatment for various brain diseases.
基金sponsored by Shanghai Education Commission Major Project(2017-01-07-00-07-E00052)National Natural Science Foundation of China(No.81773657)+1 种基金Shanghai Sailing Program(No.20YF1404500)Scientific Research Foundation of Huashan Hospital,Fudan University(No.2019QD012).
文摘There remain several intractable challenges for chemotherapy in glioma treatment,including the blood-brain barrier(BBB),blood-brain tumor barrier(BBTB),and tumor heterogeneity caused by cancer stem cells(CSCs),which are resistant to conventional chemotherapy.Here,we established a nano strategy to kill glioma cells and CSCs,combining carfilzomib and bis(diethyldithiocarbamate)copper.The synergistic drug combination disturbed cell protein metabolism at different stages and induced apoptosis and cuproptosis.The Y-shaped targeting ligand pHA-VAP-modified nanodiscs were designed to help the chemotherapeutic agents cross the BBB/BBTB and finally accumulate in tumor site.This all-stage targeting and all-stage treatment nanomedicine significantly prolonged the survival in glioma-bearing mice and might inspire the rational design of advanced drug delivery platforms.
文摘Background and Objective Patients with glioma experience a high symptom burden and have diverse palliative care needs.However,the assessment scales used in palliative care remain non-standardized and highly heterogeneous.To evaluate the application patterns of the current scales used in palliative care for glioma,we aim to identify gaps and assess the need for disease-specific scales in glioma palliative care.Methods We conducted a systematic search of five databases including PubMed,Web of Science,Medline,EMBASE,and CINAHL for quantitative studies that reported scale-based assessments in glioma palliative care.We extracted data on scale characteristics,domains,frequency,and psychometric properties.Quality assessments were performed using the Cochrane ROB 2.0 and ROBINS-I tools.Results Of the 3,405 records initially identified,72 studies were included.These studies contained 75 distinct scales that were used 193 times.Mood(21.7%),quality of life(24.4%),and supportive care needs(5.2%)assessments were the most frequently assessed items,exceeding half of all scale applications.Among the various assessment dimensions,the Distress Thermometer(DT)was the most frequently used tool for assessing mood,while the Short Form-36 Health Survey Questionnaire(SF-36)was the most frequently used tool for assessing quality of life.The Mini Mental Status Examination(MMSE)was the most common tool for cognitive assessment.Performance status(5.2%)and social support(6.8%)were underrepresented.Only three brain tumor-specific scales were identified.Caregiver-focused scales were limited and predominantly burden-oriented.Conclusions There are significant heterogeneity,domain imbalances,and validation gaps in the current use of assessment scales for patients with glioma receiving palliative care.The scale selected for use should be comprehensive and user-friendly.
基金National Key Research and Development Project(Grant No.2016YFC1101503)。
文摘Astragalus extract Astragalus polysaccharide(APS),a natural extract,has been demonstrated to exert inhibitory effects on the development of various tumors by modulating microRNA(miRNA).However,the precise regulatory mechanism of miRNA-223(miR-223)in brain glioma cells remains unclear.This study aimed to investigate the inhibitory effect of Astragalus extract APS on brain glioma cells through the miR-223/FBXW7 signaling pathway and its potential mechanism.Using the TargetScan tool,we predicted the binding between miR-223 and FBXW7 and confirmed this binding relationship through dual luciferase assay.We compared the expression of miR-223 and FBXW7 in glioma and adjacent tissues and followed up the prognosis.U87 cells were subjected to APS treatment or were transfected with small interfering RNA(siRNA)of miR-223 mimics to examine the effects of these treatments on cell proliferation,apoptosis,and FBXW7 expression.Our results demonstrated that miR-223 directly bound to FBXW7,as confirmed by dual luciferase assay.Moreover,the mRNA expression of miR-223 in glioma tissues was higher than that in paracancerous tissues,while the mRNA and protein levels of FBXW7 in glioma tissues were lower than those in paracancerous tissues.In addition,we observed a negative correlation between the expression of miR-223 and FBXW7(P<0.05).APS significantly inhibited the proliferation and invasion of U87 cells,suppressed the expression of miR-223,and promoted the expression of FBXW7(P<0.05).Transfection of miR-223 mimic into cells reversed the inhibition of miR-223 and the increase of FBXW7 induced by APS(P<0.05).Therefore,our findings suggested that APS might inhibit the proliferation and invasion of the glioma cell line U87 through the miR-223/FBXW7 signaling pathway.
基金supported by the National Natural Science Foundation of China(81560059,81760058,8160042,and 31800891)。
文摘Patients with glioma have a very high mortality rate,thus improving the poor prognosis of glioma has been the goal in the therapeutic field.Searching for more effective drugs for gliomas from natural compounds is a promising strategy.In this study,both oleanonic acid and oleanolic acid inhibited proliferation of glioma cells and reduced expression of cyclin D1 and E1,but the former has a lower IC_(50)than the latter.Oleanonic acid reduced the expression of p-STAT3 but not p-STAT1 and 5,and also reducing the expression of STAT3 in the nucleus and its transcriptional activity in glioma cells.Furthermore,knockdown of STAT3 expression inhibited proliferation and migration of glioma cells.Next,the expressions of the upstream regulators such as SIRT6 and p-JAK2 but not SIRT1,p-ERK1/2,p300 were increased by oleanonic acid.The overexpression of SIRT6 not only reduced the expression of p-STAT3 and its transcriptional activity but also inhibited the proliferation and migration of glioma cells.In addition,the effects that oleanonic acid reduced the expression of p-STAT3 and its transcriptional activity and inhibited the proliferation and migration were attenuated by the knockdown of SIRT6.Furthermore,oleanonic acid effectively suppressed glioma growth and extended survival in nude mice bearing intracerebral U87 xenografts,but not in nude mice bearing intracerebral SIRT6-knockdown U87xenografts.In conclusion,oleanonic acid upregulates the expression of SIRT6 to inactivates STAT3 and then inhibits glioma growth.
基金supported by the National Natural Science Foundation of China(Grants 82441022,82371934)Medical Science and Technology Research Project of Henan Province(SBGJ202101002)+1 种基金Joint Fund of Henan Province Science and Technology R&D Programme(225200810062)Henan Provincial Medical Science and Technology Research Joint Construction Project(LHGJ20240053,LHGJ20240036).
文摘Accurate genotyping and prognosis of glioma patients present significant clinical challenges,often dependent on subjective judgement and insufficient scientific evidence.This study aims to develop a robust,noninvasive preoperative multi-modal MRIbased transformer learning model to predict IDH genotyping and glioma prognosis.This multi-centre study included 563 glioma patients to develop an interpretable classification model utilising various preoperative imaging sequences,including T1-weighted,T2-weighted,fluid-attenuated inversion recovery,contrast-enhanced T1-weighted,and diffusion-weighted imaging.The model employs a multi-task learning framework to extract and fuse radiomic,deep learning,and clinical features for IDH genotyping and glioma prognosis.Additionally,a multi-modal transformer strategy is integrated to analyse structural and functional MRI,thereby enhancing model performance.Experimental results indicate that the model demonstrates superior performance,surpassing previous research and other state-of-the-art methods.The model achieves an AUC of 91.40% in the IDH genotyping task and 93.37% in the glioma prognosis task.Group analysis reveals that the model exhibits higher sensitivity to IDH-mutant cases and more accurately identifies low-risk groups compared to medium-or high-risk groups.This study aims to achieve accurate IDH genotyping and glioma prognosis through effective classification method,offering valuable diagnostic insights for clinical practice and expediting treatment decisions.
基金supported by the Nature Science Foundation of Chongqing(Nos.cstc2016jcyjA0838 and cstc2020jcyj-msxmX0376).
文摘Background:PLK3,which played an important role in cell cycle progression and stress response,was identified as highly expressed in various carcinomas.However,the functions,molecular characteristics,and prognostic value of PLK3 in glioma remained unexplored.Methods:We analyzed PLK3 expression in glioma samples from multiple databases.Both overexpression and knockdown of Plk3 were performed to investigate tumor cell growth in glioma,and the transplanted glioma mouse model demonstrated the role of Plk3 on tumor progression.Immunohistochemistry was conducted to detect PLK3 expression and immune cell infiltration.The trans-well assay for PLK3 on the immune cells recruitment was also determined.Additionally,we further evaluated the correlation between PLK3 and PD-1/PD-L1 as well as other immune checkpoints.Results:We found that an increased level of PLK3 was associated with malignancy and poor prognosis of glioma,and further validated that PLK3 promoted glioma progression.PLK3 also played a crucial role in immune response and was involved in Tcell immune suppression.Specifically,we revealed that CD8^(+)and CD4^(+)Tcell infiltration was decreased in Plk3 overexpressed xenografts.Furthermore,it was predicted that PLK3 was synergistic with other checkpoint members in glioma.In general,high expression of PLK3 was associated with a malignant process and poor prognosis in glioma patients.Conclusion:Our findings indicated that PLK3 expression level was highly correlated to the malignancy of gliomas,and we validated that PLK3 could promote the GBM progress in vitro and in vivo.Furthermore,PLK3 played important roles in Tcell and neutrophil immune response in glioma.Besides,the conspicuous association between PLK3 and other immune checkpoints was also observed.Crucially,high-level PLK3 expression was revealed to be related to poor clinical prognosis.These results demonstrated that PLK3 may serve as a prognostic biomarker and a potential target for glioma.
文摘Objectives:Fear of recurrence(FoR)is a common psychological burden in cerebral glioma patients.Spousal emotional support and self-disclosure may help mitigate FoR,yet their roles in this population are unclear.This study aimed to explore the association between FoR,spousal emotional support,and self-disclosure in patients with cerebral glioma.Methods:Patients with cerebral glioma were assessed using the Fear of Progression Questionnaire-Short Form(FoP-Q-SF),Perceived Social Support Scale(PSSS),Distress Disclosure Index(DDI),and Acceptance and Action Questionnaire(AAQ).Pearson correlation analysis was conducted to examine the relationships among the scale scores,while multiple linear regression analysis was performed to identify factors influencing FoR in these patients.A structural equation model(SEM)was constructed to analyze the pathways of influence among FoR,spousal emotional support,and self-disclosure.Results:FoR was significantly negatively correlated with spousal emotional support,self-disclosure,and psychological flexibility(r=−0.3986,−0.3206,−0.4547,respectively;all p<0.05),while spousal emotional support and self-disclosure were significantly positively correlated with psychological flexibility(r=0.2457,0.2776,respectively;all p<0.05).Regression analysis revealed that self-funded medical insurance,unmarried/other marital status,lack of religious belief,and lower scores of spousal emotional support,self-disclosure,and psychological flexibility were risk factors for increased FoR.The SEM demonstrated an acceptable model fit.Psychological flexibility was found to mediate the relationship between self-disclosure and FoR,indicating that self-disclosure not only had a direct negative effect on FoR but also exerted an indirect negative effect through its positive influence on psychological flexibility.Conclusion:FoR is prevalent among patients with cerebral glioma.Spousal emotional support and self-disclosure were identified as independent influencing factors of FoR.While spousal emotional support directly affected FoR,self-disclosure influenced it both directly and indirectly through the mediation of psychological flexibility.
基金supported by grants from the Natural Science Foundation of Guangxi Province(Grant No:2022GXNSFAA035639 and 2023GXNSFBA026092)the National Natural Science Foundation of China(Grant No:81860445 and 82260554)the Innovation Project of Guangxi Graduate Education(Grant No:YCBZ2024118)。
文摘Objective Glioma is a highly heterogeneous and malignant intracranial tumor that presents challenges for clinical treatment.ELMO domain containing 2(ELMOD2)is a GTPase-activating protein that regulates a range of cellular biological processes.However,its specific role and prognostic value in tumorigenesis are still unknown.This study aimed to assess the prognostic relevance and signaling function of ELMOD2 in gliomas.Methods The Chinese Glioma Genome Atlas(CGGA)and The Cancer Genome Atlas(TCGA)databases were utilized to conduct a comprehensive analysis of the expression profile of ELMOD2 in gliomas,elucidating its associations with clinicopathological parameters and patient prognosis.Single-cell analysis was performed to characterize ELMOD2 expression across distinct glioma cell subpopulations.Gene Ontology(GO),Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses,and Gene Set Variation Analysis(GSVA)were employed to evaluate the potential biological functions of ELMOD2 in gliomagenesis.Specific small interfering RNAs(siRNAs)were used to knock down ELMOD2 in the glioma cell lines U251 and A172 to assess their cellular behaviors and examine the levels of multiple key signaling molecules associated with the occurrence of gliomas.Results ELMOD2 was overexpressed in gliomas,and this upregulation was correlated with tumor grade,isocitrate dehydrogenase mutation,and 1p/19q codeletion status.Notably,ELMOD2 expression was elevated in classical and mesenchymal subtypes,and single-cell resolution analysis revealed predominant enrichment within malignant cells.Functionally,ELMOD2 regulated cell cycle progression,and its overexpression was related to independent adverse outcomes.In vitro experiments revealed that ELMOD2 was located in the cytoplasm and nucleoplasm.Furthermore,ELMOD2 knockdown reduced proliferation,migration,and invasion and increased apoptosis in U251 and A172 cell lines.Finally,ELMOD2 knockdown significantly decreased p-Erk1/2.Conclusions ELMOD2 expression in glioma is positively correlated with tumorigenesis and is a crucial independent prognostic marker.Thus,ELMOD2 is a promising biomarker and therapeutic target for glioma treatment.
文摘Objective:To systematically explore the effectiveness of combining Enhanced Recovery After Surgery(ERAS)nursing and empathy intervention for postoperative patients with glioma.Methods:A total of 54 patients with glioma undergoing surgical treatment were selected for the study.The patients were admitted to the hospital between April 2023 and April 2025.The patients were divided into an observation group(n=27)and a control group(n=27)based on a random number table method.Relevant intervention indicators were compared between the two groups.Results:Compared with the control group,the postoperative recovery indicators in the observation group showed significant differences(P<0.05).After intervention,the scores of stress psychological indicators,FMA,NHISS,and ADL in the observation group were all better than those in the control group(P<0.05).The incidence of complications in the observation group was significantly lower than that in the control group(P<0.05).Conclusion:The combined application of empathy intervention and ERAS nursing effectively regulates the postoperative stress psychological state of patients with glioma,significantly improves their limb and neurological functions as well as daily living abilities,accelerates postoperative recovery,and reduces complications.This approach is feasible for wider implementation.
基金supported by Shenzhen Science and Technology Program(JCYJ20220530152614033,JCYJ20230807142213027)Funding Statement Special Fund for Economic and Technological Development in Longgang District,Shenzhen(LGKCYLWS2023028).
文摘Objectives:Glioma,as the most lethal primary brain malignancy with poor prognosis,requires further elucidation on the functional role of long noncoding RNA(lncRNA)DDX11 antisense RNA 1(DDX11-AS1)in its pathogenesis,despite its established oncogenic functions in other cancers.Therefore,this study sought to characterize the oncogenic role and molecular mechanism of DDX11-AS1 in glioma.Methods:DDX11-AS1 expression levels were analyzed in clinical surgical glioma specimens and publicly available datasets.The functional roles of DDX11-AS1 on glioma cell proliferation and migration were investigated using in vitro knockdown and overexpression assays.In vivo tumor growth was assessed using orthotopic glioma-bearing mouse models.To elucidate the regulatory axis involving DDX11-AS1,miR-1183,and E2F transcription factor 7(E2F7),we performed competitive endogenous RNA(ceRNA)analysis and conducted functional rescue experiments via miR-1183 inhibition.Results:DDX11-AS1 expression was markedly upregulated in clinical glioma specimens.Functionally,DDX11-AS1 knockdown significantly suppressed glioma cell proliferation and migration in vitro,while its overexpression exacerbated these malignant phenotypes.Orthotopic glioma-bearingmouse models confirmed that DDX11-AS1 drives in vivo glioma tumor growth.Mechanistically,DDX11-AS1 functions as a ceRNA by competitively interacting with miR-1183.Critically,inhibition of miR-1183 rescued the suppressive effects of DDX11-AS1 knockdown on glioma tumorigenic phenotypes and restored E2F7 expression levels.Conclusions:This study demonstrates that lncRNA DDX11-AS1 promotes glioma progression by regulating the miR-1183/E2F7 axis,indicating a potential therapeutic target for glioma.
基金supported by the Natural Science Foundation of Hebei Province(H2021206037)the Government-funded Project on Training of Outstanding Clinical Medical Personnel of Hebei Province in the year 2021(303-16-20-06)the Medical Research Project of Hebei Provincial Health Commission(20230031).
文摘Background:Glioma is the most common tumor of the central nervous system with a poor prognosis.This study aims to explore the role of calcium/calmodulin-dependent protein kinase IIβ(CAMK2B)in regulating the malignant progression of glioma cells,as well as the molecular mechanisms underlying these malignant behaviors.Methods:The correlation between CAMK2B expression in gliomas and patient prognosis was analyzed using immunohistochemistry,quantitative reverse transcription polymerase chain reaction(qRT-PCR),and western blot.Furthermore,the study explored the role of CAMK2B in glioma cell proliferation,invasion,and migration using cell counting kit-8(CCK-8),5-Ethynyl-2′-deoxyuridine(EdU),wound healing,transwell,and in vivo tumor xenograft assays.Result:Patients with high CAMK2B expression exhibited significantly better prognostic outcomes compared to those with low expression levels.Furthermore,CAMK2B expression was significantly lower in glioma tissues and cells compared to both normal brain tissue and human astrocyte cell lines.Notably,overexpression of CAMK2B in glioma cells led to an approximate 40%reduction in proliferative capacity and a 60–70%decrease in invasive and migratory abilities,compared to control glioma cells.These differences were statistically significant at p<0.05.Conversely,knockdown of CAMK2B using siRNA-CAMK2B significantly enhanced the proliferative,invasive,and migratory capabilities of glioma cells in both in vitro and in vivo settings,enhancing these abilities by 1.5 to 3 times.Notably,these effects were reversed through the application of the Rat Sarcoma viral oncogene homolog(Ras)pathway inhibitor,Salirasib.Western blot analysis revealed that knockdown of CAMK2B led to activation of the Ras/Rapidly Accelerated Fibrosarcoma(Raf)/Mitogen-activated protein kinase kinase(MEK)/Extracellular signal-regulated kinase(ERK)signaling pathway in glioma cell lines,whereas overexpression of CAMK2B resulted in the suppression of this pathway.Conclusion:CAMK2B inhibits glioma proliferation,invasion,andmigration through the Ras/Raf/MEK/ERK signaling pathway.
